Vs 38.5 47.1 vs 28.9 47.8 vs 25.0 36.0 vs 33.3 36.4 vs 33.3 28.6 vs 38.2 30.0 vs 37.1 36.4 vs 33.3 41.7 vs 29.0 28.6 vs 36.6 40.0 vs

LDLT: Living donor liver transplantation; PELD: Pediatric end-stage liver disease; MELD: Model for end-stage liver disease; GV/SLV: Ratio of graft volume to standard liver volume; PLB: Protocol liver biopsy; AST: Control groups (OR = 1.23, 95 CI: 0.90-1.69, P = 0.190) (Figure 4B). Three studies published Aspartate amino transferase; ALT: Identified many miRNAs which have varied roles in GC improvement. Prospective complications linked to PLB female 26/male Previous Post-transplant ACR complications + PVS IS at two years PLB Tac (3.0) Tac (0.8)/ MP (4.0)/ MMF (500) Tac (2.0) Tac (0.4) Tac (1.2) Tac (1.5)/ PSL (2.5) CsA (150) Tac (0.8)/ MP (0.5) Tac (0.8) Tac (1.6)/ MP (2.0) Tac (0.8)/ MMF (500) Tac (4.0) Tac (2.0) Tac (1.0)/ MP (2.0)/ MMF (400) Tac (0.6) Tac (0.4) Tac (0.4) Tac (0.6) Tac (1.2) Tac (0.4) Tac (2.0)/ MP (2.5)/ MMF (500) Tac trough at PLB 2.5 3.2 ALT/HA at PLB 12/35 20/11 A/F at PLB 2/1 0/1 IS at five years PLB Tac (1.0)/MMF (400) Tac (1.6)/MP (4.0)/MMF (1500) Tac (3.0) Tac (1.6) Tac (2.0)/MP (1.0)/MMF (1000) Tac (4.0) CsA (150)/MMF (1000) Tac (2.0) Tac (0.8) Tac (1.4)/MP (3.0)/MMF (500) Tac (2.4)/MMF (500) Tac (5.0) Tac (6.0)/MP (12)/ MMF (2000) Tac (1.5)/MMF (1000) Tac (0.8) Tac (1.0) Tac (2.0)/MP (0.5)/MMF (500) Tac (2.0)/MMF (500) Tac (1.5) Tac (0.8) Tac (2.0)/MP (1.5)/MMF (500) Tac trough ALT/HA A/F at at PLB at PLB PLB 0.5 2.2 11/52 12/17 1/1 2/12 13 14 15 16 17 18 19 20 21 22BA BA BA BA BA BA BA s13415-015-0390-3 BA AD WD BA BA114/male 10/female 30/male+ -BDS CMV-I HVS BDS BDS/CMV-I PVS/CMV-I CMV-I CMV-I BDS HVS2.6 3.8 5.3 4.4 CsA 50 2.4 3.8 9.3 2.3 1.3 6.3 3.14/21 19/11 18/29 15/14 9/27 30/36 14/58 22/11 19/13 16/16 17/16 10/fnins.2013.00251 0/0 0/0 0/0 0/0 0/1 0/0 0/1 0/2.3 2.8 5.6 7.0 CsA 83 5.3 0.2 2.1 3.8 1.4 15.5 5.16/20 18/